Targeting BRAF for patients with melanoma

The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising activity in early clinical development and particular interest is focused on selective inhibitors of...

Descripción completa

Detalles Bibliográficos
Autores principales: Arkenau, H-T, Kefford, R, Long, G V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049553/
https://www.ncbi.nlm.nih.gov/pubmed/21139585
http://dx.doi.org/10.1038/sj.bjc.6606030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049553/
https://www.ncbi.nlm.nih.gov/pubmed/21139585
http://dx.doi.org/10.1038/sj.bjc.6606030

Ejemplares similares